How to Store Semax: Stability and Handling, Per the Research

Answer first: what the record covers and what it does not

Semax is a synthetic heptapeptide based on the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro tail; the N-acetylated variant carries an acetyl group on the N-terminus. Searches for storage guidance usually expect a shelf-life number. The honest position is that no published shelf-life or accelerated-stability trial for Semax appears in the indexed literature. The Semax papers that exist are pharmacological rather than pharmaceutical: researchers examined enzyme interactions in human serum (Bioorganicheskaia khimiia, 2001), aminopeptidase-mediated proteolysis of Semax analogues (Bioorganicheskaia khimiia, 2011), and in vivo neurological outcomes such as functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025) — not container-closure systems, expiry dating or freeze-thaw cycling.

Everything below is labelled as either Semax-specific published chemistry or general peptide formulation science. The second category is standard physical chemistry that applies to small synthetic peptides as a class; it is not evidence about this molecule in particular, and this page does not convert it into instructions. Broader storage principles across peptide classes are covered in the peptide storage guide, and the compound overview sits at N-Acetyl Semax.

Semax-specific chemistry relevant to stability

The Pro-Gly-Pro tail and enzymatic resistance

Semax's C-terminal Pro-Gly-Pro motif belongs to the glyproline family, which a 2005 review discussed as a class of regulatory peptides characterised by their stability and used as the basis for hybrid or "chimeric" constructs (Pathophysiology, 2005). This is biological stability — resistance to peptidases in tissue and plasma — and it is not the same property as stability in a vial. A peptide can resist enzymatic cleavage in blood while still being vulnerable to hydrolysis, oxidation or adsorption in an aqueous solution sitting on a bench.

Proteolysis and the N-terminus

Researchers compared Semax analogues bearing different N-terminal amino acids and reported that the identity of that residue influenced how readily aminopeptidases cleaved the molecule (Bioorganicheskaia khimiia, 2011). In a separate line of work, the study of N-terminal acetylation examined how blocking that terminus altered copper(II) and zinc(II) coordination as well as biological properties of the peptide (Journal of Inorganic Biochemistry, 2016). Both findings matter for storage discussions because they describe what is chemically reactive at the N-terminus — an unmodified α-amino group is also the site involved in metal binding and in several non-enzymatic degradation pathways — but neither paper measured powder or solution stability over time.

Metal coordination as a degradation-relevant variable

The same acetylation study reported that Semax coordinated copper(II) and zinc(II) ions and that N-terminal acetylation changed that coordination chemistry (Journal of Inorganic Biochemistry, 2016). In general peptide chemistry — not a Semax finding — bound transition metals can catalyse oxidative side reactions in solution, which is the reason trace-metal content of diluents and glassware is a routine variable in formulation work. The published Semax record establishes the binding; it does not establish any rate of metal-catalysed degradation for this peptide.

Oxidation-sensitive residues

Semax contains methionine at its N-terminus. Methionine sulfoxide formation is a textbook oxidation pathway for peptides and proteins generally; this is general chemistry, not a reported Semax stability measurement. A 2025 review of bioactive peptides and proteins/polypeptides discussed peptide modulation of oxidative stress pathways in neurodegenerative disease (Neuropeptides, 2025), which concerns biological antioxidant signalling rather than oxidation of a peptide inside a storage vial — the two are frequently conflated in secondary writing and should not be.

In vivo clearance is not shelf life

A rat study tracked the kinetics of Semax penetration into brain and blood after intranasal administration (Bioorganicheskaia khimiia, 2006). Rapid in vivo appearance and disappearance describes distribution and metabolism in a living animal. It says nothing about how long the molecule remains intact in a sealed container, and pages that cite short biological half-life as a storage argument are misreading the source.

Lyophilised powder versus reconstituted solution

The single largest distinction in any peptide storage discussion is physical state. The following points are general peptide formulation science, offered as background rather than as Semax data:

• Lyophilisation (freeze-drying) removes the water that acts as the reaction medium for hydrolysis and deamidation, which is why dry peptide cakes are conventionally the more stable presentation.
• Once a powder is dissolved, hydrolysis, oxidation, aggregation and adsorption to container surfaces all become possible; dilute solutions of small peptides are also prone to surface losses.
• Residual moisture, headspace oxygen, light exposure, pH of the diluent, buffer species and trace metals are the variables that formulation scientists manipulate when they test stability.
• Cold storage slows chemical reaction rates; it does not stop microbial growth indefinitely, and it does not reverse degradation that has already occurred.

None of these principles has been quantified for Semax in a published trial. Research groups working with the peptide — for example the team that reported effects on rat basal forebrain cholinergic neurons (Restorative Neurology and Neuroscience, 2008) and the group reporting functional recovery after spinal cord injury in mice (British Journal of Pharmacology, 2025) — prepared solutions for experimental administration, but those papers described pharmacology and did not publish stability data for the solutions used.

Does Semax need refrigeration? What can and cannot be said

No published study compared refrigerated versus room-temperature Semax over time. Supplier and manufacturer documentation for research-grade peptides commonly specifies cold or frozen storage for lyophilised material and refrigeration for solutions after reconstitution, with shorter assigned periods for the latter. Those are vendor-assigned specifications, not peer-reviewed findings, and they vary between suppliers for the same molecule. In regulated pharmaceutical practice, a storage condition and expiry date are assigned only after formal stability testing under defined temperature and humidity conditions; no such public dataset exists for Semax as a research chemical.

Shelf life, expiry dating and travel

An expiry date is a regulatory construct: it is the end of a period during which a product met its specification under tested conditions. Research-grade peptides sold for laboratory use are frequently labelled with a "use by" or "retest" date derived from supplier convention rather than from published, molecule-specific stability data. For Semax, the indexed literature contains no such dataset, so any specific number of months circulating online is not traceable to a peer-reviewed source.

Temperature excursions during shipping and travel are the practical case where this matters most. General formulation science holds that degradation is time-and-temperature dependent, so a brief warm excursion is a different proposition from prolonged ambient storage — but the magnitude of that difference for Semax specifically has not been published. Pages that quote precise percentage losses for Semax at particular temperatures are not drawing on an identifiable study.

Signs of degradation and product identity: what studies report

Visual inspection is a weak tool. Discolouration, cloudiness in a previously clear solution, visible particulates, or a collapsed or shrunken lyophilised cake are the changes most often described in general formulation practice, but a peptide can lose potency through hydrolysis or oxidation with no visible change at all. Confirming identity and purity requires analytical methods such as HPLC and mass spectrometry.

Analytical quality is a documented problem for this compound class. A study of seized pharmaceutical preparations reported the occurrence of putative cognitive-enhancing research peptides in such products, and the authors framed the finding as an incentive for controlling agencies to prepare for further encounters of this kind (Drug Testing and Analysis, 2020). That report concerns what was present in seized material rather than storage per se, but it illustrates why unverified material makes storage questions moot: degradation cannot be meaningfully discussed for a vial whose starting identity and content are unconfirmed.

Related chemistry occasionally cited in storage discussions

Work on arachidonoyl amino acids and arachidonoyl peptides described the synthesis and properties of lipid-conjugated peptide derivatives (Bioorganicheskaia khimiia, 2006), and researchers reported that Semax and Selank inhibited enkephalin-degrading enzymes from human serum (Bioorganicheskaia khimiia, 2001). Both are sometimes invoked in online discussions of Semax "stability". Neither addressed storage conditions; the first concerns synthetic chemistry of modified peptides and the second concerns enzyme inhibition in serum.

What remains unestablished

1. No published refrigerated-versus-ambient comparison for Semax powder or solution.
2. No published freeze-thaw cycling data for Semax.
3. No published post-reconstitution stability window supported by analytical measurement.
4. No published light-exposure or container-material study for this peptide.
5. Human clinical pharmacology literature in English is limited, and the animal studies cited here — including neonatal injection work in mice of different genotypes (Zh Vyssh Nerv Deiat, 2004) and experimental work on optic-nerve disease models (Vestnik Oftalmologii, 2004) — reported biological outcomes, not formulation stability.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. It summarises what researchers reported and what general peptide chemistry describes, and it does not tell anyone how to handle, prepare or administer any substance. Semax is not an approved drug in the United States and is handled as a research chemical in most jurisdictions.

References

• [Semax and selank inhibit the enkephalin-degrading enzymes from human serum] (Bioorganicheskaia khimiia, 2001)
• [Neonatal Semax and saline injections induce open-field behavior changes in mice of different genotypes] (Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2004)
• [An experimental substantiation for using the "Semax" neuroprotector in the treatment of optic-nerve diseases] (Vestnik oftalmologii, 2004)
• Natural and hybrid ("chimeric") stable regulatory glyproline peptides (Pathophysiology, 2005)
• [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration] (Bioorganicheskaia khimiia, 2006)
• [Arachidonoyl amino acids and arachidonoyl peptides: synthesis and properties] (Bioorganicheskaia khimiia, 2006)
• Effects of behaviorally active ACTH (4-10) analogue - Semax on rat basal forebrain cholinergic neurons (Restorative Neurology and Neuroscience, 2008)
• [Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases] (Bioorganicheskaia khimiia, 2011)
• Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties (Journal of Inorganic Biochemistry, 2016)
• The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations (Drug Testing and Analysis, 2020)
• Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025)
• Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: Targeting oxidative stress in neurodegenerative diseases (Neuropeptides, 2025)